C.K. McWhorter Cancels J.P. Morgan Communications, Citing Lack of Inclusivity in Minority Banking Initiatives
Globe Newswire27-03-2024, 00:38
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00